Biotech News
Related news
INABIN8bio2026-07-09 12:00 EST
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
INABIN8bio2026-08-06 20:01 EST
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
CGEMCullinan Therapeutics, Inc.2026-06-10 11:30 EST
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
FATEFate Therapeutics2026-07-01 20:05 EST
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
MMSIMerit Medical2026-08-05 16:00 EST
Merit Medical to Participate in Upcoming Investors Conferences in August
IDYAIDEAYA Biosciences2026-07-17 13:00 EST
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
CHRSCoherus BioSciences, Inc.2026-06-23 18:00 EST
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
NRIXNurix Therapeutics2026-08-04 11:00 EST
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
MGNXMacroGenics2026-07-23 20:01 EST
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
IMTXImmatics2026-07-17 14:25 EST
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
IN8bio
Gamma-Delta T-Cell Therapies IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease. The platform seeks to use the innate and adaptive properties of gamma-delta T cells to recognize stressed or malignant cells. Glioblastoma Program The company's clinical work in glioblastoma evaluates...
Recent company news
INABIN8bio2026-08-10 20:01 EST
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INABIN8bio2026-08-06 20:01 EST
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
INABIN8bio2026-07-09 12:00 EST
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
INABIN8bio2026-06-03 12:30 EST
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
INABIN8bio2026-06-01 12:30 EST
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
Stock data
- Close
- 1.28 USD
- Market cap
- 14.96M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States